Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
Outcomes for patients with acute myeloid leukemia (AML) have improved due to advances in therapeutic approaches in combination with improvements in supportive care. However, relapse remains a significant clinical challenge and research has focused on maintenance strategies to extend remission and overall survival in patients with AML.1
Sorafenib as maintenance therapy for patients with transplant-ineligible or post-alloSCT AML
Musa Yilmaz, MD
The University of Texas MD Anderson Cancer Center, Houston, TX
Promising emerging therapies for AML and the challenges that remain
Paresh Vyas, MRCP, FRCP, FRCPath
Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
Azacitidine and venetoclax plus gilteritinib in the treatment of FLT3-mutated AML
Farhad Ravandi, MD
The University of Texas MD Anderson Cancer Center, Houston, TX
Trends in alloSCT for good-risk AML: a longitudinal study
Arnon Nagler, MD
Chaim Sheba Medical Center, Tel-Aviv, Israel
ASH 2023: The current landscape of immunotherapy for AML
Jacqueline Garcia, MD
Dana-Farber Cancer Institute, Boston, MA
Advancements in AML: an update from ASH 2023
Marina Konopleva, MD, PhD
Albert Einstein College of Medicine, New York City, NY
FLT3-ITD-specific MRD predicts outcomes of chemotherapy in AML
Mark Levis, MD, PhD
Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
Poor outcomes of patients with AML who relapse underscores the need for effective initial treatment
Farhad Ravandi, MD
The University of Texas MD Anderson Cancer Center, Houston, TX
Personalizing AML treatment by targeting MRD mutations
Mark Levis, MD, PhD
Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
KOMET-008: a Phase I trial of ziftomenib combinations in KMT2A-rearranged or NPM1-mutant AML
Aaron Goldberg, MD, PhD
Memorial Sloan-Kettering Cancer Center, New York, NY
AUGMENT-101 trial: revumenib in patients with R/R KMT2Ar acute leukemia
Ibrahim Aldoss, MD
City of Hope, Duarte, CA
Phase I trial of the menin inhibitor JNJ-75276617 in patients with acute leukemia
Elias Jabbour, MD
The University of Texas MD Anderson Cancer Center, Houston, TX
First-line venetoclax plus HMA vs intensive chemotherapy in older adults with IDH-mutated AML
Keri Maher, DO
VCU Health, Richmond, VA
Improving long-term outcomes with intensive chemotherapy in AML: looking to the future
Christoph Röllig, MD, MSc
Dresden University of Technology, Dresden, Germany
131I-apamistamab-led induction/conditioning prior to alloSCT in R/R AML: insights from SIERRA
Mark Litzow, MD
Mayo Clinic, Rochester, MN
Stem cell transplantation conditioning in AML: making the decision between MAC and RIC
Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, FMedSci, University of Birmingham, Birmingham, UK
Oral combination of ASTX727 (decitabine/cedazuridine) plus Ven for older/unfit patients with AML
Farhad Ravandi, MD
The University of Texas MD Anderson Cancer Center, Houston, TX
Impact of recent advancements in treatment of R/R AML on OS in clinical practice
Keri Maher, DO
VCU Health, Richmond, VA
Induction therapy on post-transplant outcomes
Nicholas Short, MD
MD Anderson Cancer Center, Houston, TX
Novel transplant strategies, and reducing the risk of relapse
Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil
Queen Elizabeth Hospital, Birmingham, UK
Maintenance therapy: agents under investigation and future outlooks
Thomas Cluzeau, MD, PhD
University Hospital of Nice, Nice, France
Novel immunotherapies in AML and insights into the future of the treatment landscape
Marion Subklewe, MD
Ludwig-Maximilians-University of Munich, Munich, Germany
Improving maintenance therapy in AML: exploring the role of IDH inhibitors
Amir Fathi, MD, MPH
Massachusetts General Hospital, Boston, MA
Ongoing clinical trials and targeted therapies
VENTOGRAFT trial: AZA, VEN, and DLI in patients
with MDS and AML who have relapsed following alloSCT
Thomas Cluzeau, MD, PhD
University Hospital of Nice, Nice, France
Gilteritinib as post-transplant maintenance therapy
in FLT3-ITD AML
Mark Levis, MD, PhD
Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
Relapse in AML
Treatment approaches for patients with R/R AML and the importance of preventing relapse
Alessandro Isidori, MD, PhD
Marche Nord Hospital, Pesaro, Italy
Approaching patients with MDS and AML who relapse after alloSCT & strategies to prevent relapse
Pramila Krishnamurthy, MA, FRCPath, MRCP, PhD
King’s College Hospital NHS Foundation Trust, London, UK
Reference:
1. Reville, P.K. and Kadia, T.M. Maintenance therapy in AML. Frontiers in Oncology 2021;10:619085. doi:10.3389/fonc.2020.619085.
5:18
Glossary
AML, acute myeloid leukemia
This educational activity has received independent medical education support from Bristol Myers Squibb. This supporter has no influence over the production of the content.
